Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis
Cancers · 09.11.2023 · 15 (22) · 5339
DOI: 10.3390/cancers15225339 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 09.11.2023. Verfasst von Reem Halabi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological and Chemical Sciences, Lebanese International University, Beirut 1105, Lebanon. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Library (QNL).
Abstract (Originalsprache)
Meningiomas are the most prevalent primary intracranial tumors. The majority are benign but can undergo dedifferentiation into advanced grades classified by World Health Organization (WHO) into Grades 1 to 3. Meningiomas’ tremendous variability in tumor behavior and slow growth rates complicate their diagnosis and treatment. A deeper comprehension of the molecular pathways and cellular microenvironment factors implicated in meningioma survival and pathology is needed. This review summarizes the known genetic and epigenetic aberrations involved in meningiomas, with a focus on neurofibromatosis type 2 (NF2) and non-NF2 mutations. Novel potential biomarkers for meningioma diagnosis and prognosis are also discussed, including epigenetic-, RNA-, metabolomics-, and protein-based markers. Finally, the landscape of available meningioma-specific animal models is overviewed. Use of these animal models can enable planning of adjuvant treatment, potentially assisting in pre-operative and post-operative decision making. Discovery of novel biomarkers will allow, in combination with WHO grading, more precise meningioma grading, including meningioma identification, subtype determination, and prediction of metastasis, recurrence, and response to therapy. Moreover, these biomarkers may be exploited in the development of personalized targeted therapies that can distinguish between the 15 diverse meningioma subtypes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biological and Chemical Sciences, Lebanese International University, Beirut 1105, Lebanon.
- Department of Experimental Pathology, Microbiology and Immunology and Center for Infectious Diseases Research, Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon.
- Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.
- Department of Biology, University of Florida, Gainesville, FL 32601, USA.
- Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut 1107, Lebanon.
- Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.
ORCID-Profile: Fatima Dakroub, Mohammad Z Haider, Stuti Patel, Mohammad A Reslan, Ali H Eid, Yehia Mechref, Nadine Darwiche, Firas Kobeissy, Abdullah A Shaito
Förderung
- Qatar National Library (QNL)
Zitieren
APA
Halabi, R., Dakroub, F., Haider, M. Z., Patel, S., Amhaz, N. A., Reslan, M. A., Eid, A. H., Mechref, Y., Darwiche, N., Kobeissy, F., Omeis, I., & Shaito, A. A. (2023). Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis. Cancers, 15(22), 5339. https://doi.org/10.3390/cancers15225339
Vancouver
Halabi R, Dakroub F, Haider MZ, Patel S, Amhaz NA, Reslan MA, et al. Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis. Cancers. 2023;15(22):5339. doi:10.3390/cancers15225339
BibTeX
@article{Halabi2023,
author = {Halabi, Reem and Dakroub, Fatima and Haider, Mohammad Z and Patel, Stuti and Amhaz, Nayef A and Reslan, Mohammad A and Eid, Ali H and Mechref, Yehia and Darwiche, Nadine and Kobeissy, Firas and Omeis, Ibrahim and Shaito, Abdullah A},
title = {Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis},
journal = {Cancers},
year = {2023},
volume = {15},
number = {22},
pages = {5339},
doi = {10.3390/cancers15225339}
}
EUVIMED